Assessing Alnylam Pharmaceuticals (ALNY) Valuation After First Profitable Year And Rapid Revenue Growth

Simply Wall St.

02/20

Alnylam Pharmaceuticals (ALNY) is back in focus after its latest earnings report, where revenue for 2025 reached US$3.71 billion and the company reported full-year net income of US$313.75 million. See...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2612239796"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612239796\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612239796?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-20 06:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612239796","market":"sg","top_or_hot":-1,"title":"Assessing Alnylam Pharmaceuticals (ALNY) Valuation After First Profitable Year And Rapid Revenue Growth","media":"Simply Wall St.","content":"<div>\n<p>Alnylam Pharmaceuticals (ALNY) is back in focus after its latest earnings report, where revenue for 2025 reached US$3.71 billion and the company reported full-year net income of US$313.75 million. See...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/assessing-alnylam-pharmaceuticals-alny-valuation-after-first\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Alnylam Pharmaceuticals (ALNY) Valuation After First Profitable Year And Rapid Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Alnylam Pharmaceuticals (ALNY) Valuation After First Profitable Year And Rapid Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-20 06:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/assessing-alnylam-pharmaceuticals-alny-valuation-after-first><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alnylam Pharmaceuticals (ALNY) is back in focus after its latest earnings report, where revenue for 2025 reached US$3.71 billion and the company reported full-year net income of US$313.75 million. See...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/assessing-alnylam-pharmaceuticals-alny-valuation-after-first\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALNY","symbol_name":"阿尔尼拉姆制药公司","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/assessing-alnylam-pharmaceuticals-alny-valuation-after-first","article_id":"2612239796","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/assessing-alnylam-pharmaceuticals-alny-valuation-after-first","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612239796","pubTimestamp":1771540148,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Alnylam Pharmaceuticals (ALNY) is back in focus after its latest earnings report, where revenue for 2025 reached US$3.71 billion and the company reported full-year net income of US$313.75 million.\nSee our latest analysis for Alnylam Pharmaceuticals.\nThe share price has been volatile, with a 10.01% 7 day share price return and a 22.23% decline over 90 days. However, the long term total shareholder return of 35.21% over 1 year and 131.51% over 5 years points to stronger momentum over multi year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ALNY":"阿尔尼拉姆制药公司"},"translate_title":"在第一个盈利年和收入快速增长后评估Alnylam Pharmaceuticals(ALNY)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1.5},"content_text":"Alnylam Pharmaceuticals (ALNY) is back in focus after its latest earnings report, where revenue for 2025 reached US$3.71 billion and the company reported full-year net income of US$313.75 million. See our latest analysis for Alnylam Pharmaceuticals. The share price has been volatile, with a 10.01% 7 day share price return and a 22.23% decline over 90 days. However, the long term total shareholder return of 35.21% over 1 year and 131.51% over 5 years points to stronger momentum over multi year periods. The recent rebound around earnings and the US$2.26b shelf registration filing suggests investors are reassessing both growth potential and risk. If Alnylam’s RNAi story has your attention, it could be a good moment to broaden your view with our screener of 25 healthcare AI stocks. See what else is shaping biotech right now. With Alnylam now profitable, a US$3.71b revenue base, a US$339.37 share price, and analyst targets and intrinsic estimates sitting higher, you have to ask: is there still upside here, or is future growth already priced in? AdvertisementMost Popular Narrative: 31% Undervalued Alnylam’s fair value in the most followed narrative sits at about $491.92 versus the last close of $339.37, which is a sizable gap investors are weighing.  The strong track record of rapid health system integration and scalable commercial execution, with SG&A and R&D investments offset by exceptional sales growth, points to the start of meaningful operational leverage, improving net margins as product revenues outpace fixed cost escalation.  Read the complete narrative. Curious what earnings path sits behind that valuation gap, and how much margin expansion is baked in over time? The full narrative lays out the numbers driving that $491.92 figure and the assumptions that support it. Result: Fair Value of $491.92 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, those upside assumptions still face pressure from Alnylam’s dependence on the TTR franchise and the risk that payer or pricing shifts squeeze margins faster than expected. Find out about the key risks to this Alnylam Pharmaceuticals narrative. Another View: Rich P/E Puts Pressure On The Story While the SWS model and narratives point to undervaluation on future cash flows, the current P/E of 140.6x is far above both the US Biotechs industry at 22.3x and the peer average at 18x, and even above the 33.7x fair ratio our analysis suggests the market could move toward. That gap leaves you weighing more valuation risk on today’s price, even if you accept the growth case. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ALNY P/E Ratio as at Feb 2026Next Steps The mix of optimism and concern in this story is clear, so it makes sense to move quickly and check the underlying data yourself. To see how the positives and drawbacks compare side by side, take a look at our breakdown of 4 key rewards and 1 important warning sign. Looking for more investment ideas? If this update has sharpened your thinking on Alnylam, do not stop here, you will miss other opportunities if you do not widen your search.  Target potential value upside by scanning our list of 53 high quality undervalued stocks built from companies with pricing that may not reflect their fundamentals. Lock in potential income ideas by reviewing 13 dividend fortresses that focus on higher yield payouts for investors who care about cash returns. Prioritize resilience by searching through 80 resilient stocks with low risk scores designed for investors who want steadier profiles and fewer unpleasant surprises.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}